• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584

Recent Advances in the Application of 4-(Pyridazin-3-yl)benzaldehyde (CAS: 328125-39-9) in Chemical Biology and Pharmaceutical Research

4-(Pyridazin-3-yl)benzaldehyde (CAS: 328125-39-9) has emerged as a versatile building block in medicinal chemistry and chemical biology research. Recent studies have highlighted its potential as a key intermediate in the synthesis of novel bioactive compounds targeting various disease pathways. This aldehyde derivative combines the unique electronic properties of the pyridazine ring with the reactivity of a benzaldehyde group, making it particularly valuable for the development of small-molecule inhibitors and probes.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 4-(pyridazin-3-yl)benzaldehyde in the synthesis of selective kinase inhibitors. Researchers successfully incorporated this scaffold into a series of compounds showing nanomolar activity against specific tyrosine kinases involved in cancer progression. The electron-deficient nature of the pyridazine ring was found to enhance binding interactions with the ATP-binding pocket of target kinases.

In pharmaceutical development, this compound has gained attention for its role in creating PROTAC (Proteolysis Targeting Chimera) molecules. A recent patent application (WO2023056321) describes its use as a linker component connecting target protein binders to E3 ubiquitin ligase recruiters. The rigidity and appropriate length of the 4-(pyridazin-3-yl)benzaldehyde structure were shown to optimize the spatial orientation required for effective protein degradation.

Metabolic stability studies published in Xenobiotica (2023) revealed that derivatives containing the 4-(pyridazin-3-yl)benzaldehyde moiety exhibit favorable pharmacokinetic properties, including improved microsomal stability compared to similar compounds with alternative heterocyclic systems. This finding suggests potential advantages for drug candidates incorporating this structural feature.

Recent synthetic methodology developments have expanded access to 4-(pyridazin-3-yl)benzaldehyde derivatives. A 2024 Organic Letters publication described a novel palladium-catalyzed cross-coupling approach that significantly improves the yield and purity of this intermediate, addressing previous challenges in large-scale production. This advancement is expected to facilitate more extensive structure-activity relationship studies.

Emerging applications in chemical biology include the use of 4-(pyridazin-3-yl)benzaldehyde as a fluorescent probe precursor. Research in ACS Chemical Biology demonstrated that Schiff base formation with this compound creates environment-sensitive fluorophores useful for monitoring protein conformational changes and protein-protein interactions in live cells.

The compound's safety profile has been evaluated in recent toxicological studies. Data presented at the 2023 Society of Toxicology annual meeting indicated low acute toxicity (LD50 > 2000 mg/kg in rodent models) and minimal genotoxic potential, supporting its suitability for further pharmaceutical development.

Future research directions highlighted in recent reviews include exploring the compound's potential in covalent inhibitor design (taking advantage of the aldehyde group's reactivity with nucleophilic amino acids) and its application in metal-organic frameworks for drug delivery systems. The unique combination of hydrogen bond acceptor sites and planar geometry makes this scaffold particularly interesting for these applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)